Genetics of glioblastoma: a window into its imaging and histopathologic variability.
暂无分享,去创建一个
Keith Paulsen | David W Roberts | Cong Ran | K. Paulsen | M. Israel | D. Roberts | D. Pastel | C. Fadul | B. Harris | Camilo E Fadul | Pablo A Valdes | Mark A Israel | P. Valdes | Brent T Harris | Clifford J Belden | David A Pastel | C. Belden | C. Ran
[1] H. Shimizu,et al. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. , 2000, AJNR. American journal of neuroradiology.
[2] M. Frosch,et al. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[4] G. Riggins,et al. A survey of glioblastoma genomic amplifications and deletions , 2009, Journal of Neuro-Oncology.
[5] Catherine Dumur,et al. Microarray Analysis of MRI-defined Tissue Samples in Glioblastoma Reveals Differences in Regional Expression of Therapeutic Targets , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[6] A. Harris,et al. Mechanisms of resistance to antiangiogenesis therapy. , 2010, European journal of cancer.
[7] D. Louis. The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.
[8] M. Chamberlain. Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.
[9] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[10] Erwin G. Van Meir,et al. Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.
[11] D. Leavesley,et al. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen , 1992, The Journal of cell biology.
[12] I. Date,et al. Angiogenesis and invasion in glioma , 2011, Brain Tumor Pathology.
[13] P. Wen,et al. Bevacizumab for recurrent malignant gliomas , 2008, Neurology.
[14] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[15] Hiroyuki Kabasawa,et al. Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. , 2005, Surgical neurology.
[16] Giuseppe Sciumè,et al. Chemokines and glioma: Invasion and more , 2010, Journal of Neuroimmunology.
[17] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.
[19] P. Wen,et al. Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.
[20] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[21] G. Gores,et al. Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[23] Tracy T Batchelor,et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.
[24] W. Broaddus,et al. The Role of Matrix Metalloproteinase Genes in Glioma Invasion: Co-dependent and Interactive Proteolysis , 2001, Journal of Neuro-Oncology.
[25] W. A. Galloway,et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. , 1998, British journal of clinical pharmacology.
[26] Ru-Fang Yeh,et al. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. , 2010, Radiology.
[27] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[28] Yiping Deng,et al. Expression of Matrix Metalloproteinase-26 promotes human glioma U251 cell invasion in vitro and in vivo. , 2009, Oncology reports.
[29] B. Aggarwal. Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.
[30] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[31] M. Weller,et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.
[32] E. Jouanneau. ANGIOGENESIS AND GLIOMAS: CURRENT ISSUES AND DEVELOPMENT OF SURROGATE MARKERS , 2008, Neurosurgery.
[33] K. Aldape,et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.
[34] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[35] Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics , 2010, Molecular Cancer.
[36] P. Meltzer,et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.
[37] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[38] C. Dullin,et al. Tumor localization of an anti-TGF-β antibody and its effects on gliomas. , 2010, International journal of oncology.
[39] Paul S Mischel,et al. MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.
[40] M. Martínez-Bisbal,et al. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[41] Christopher Logothetis,et al. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.
[42] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Mahlon D. Johnson,et al. Vascular gene expression patterns are conserved in primary and metastatic brain tumors , 2010, Journal of Neuro-Oncology.
[44] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[45] G. Fuller,et al. Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.
[46] Andrew D Norden,et al. Therapeutic strategies for inhibiting invasion in glioblastoma , 2009, Expert review of neurotherapeutics.
[47] Inna N Lavrik,et al. Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.
[48] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[50] T. Mikkelsen,et al. Targeting integrins in malignant glioma , 2010, Targeted Oncology.
[51] M. Essig,et al. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes , 2010, Acta Neuropathologica.
[52] Paul S Mischel,et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.
[53] D. Ashley,et al. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells , 2001, Oncogene.
[54] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[55] E. Holland,et al. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. , 2005, Cancer research.
[56] A. Wesołowska,et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion—an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor , 2008, Oncogene.
[57] R. Mahfouz,et al. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. , 2007, Blood cells, molecules & diseases.
[58] A. Jackson,et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? , 2006, AJNR. American journal of neuroradiology.